Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–178. doi:10.1002/nau.1005211857671
   PubMed Web of Science ®Google Scholar
• Fantl AJ. Urinary Incontinence in Adults: Acute and Chronic Management/Urinary Incontinence in Adults. Guideline Panel Update. Rockville (MD): U.S. Department of Health and Human Services; 1996. Agency for Health Care Policy and Research; Clinical Practice Guideline Number 2: AHCPR publication no. 96-0682.
   Google Scholar
• Ebbesen MH, Hunskaar S, Rortveit G, et al. Prevalence, incidence and remission of urinary incontinence in women: longitudinal data from the Norwegian HUNT study (EPINCONT). BMC Urol. 2013;13(1):27. doi:10.1186/1471-2490-13-2723721491
   PubMed Web of Science ®Google Scholar
• Sacco E, Prayer-Galetti T, Pinto F, et al. Urinary incontinence after radical prostatectomy: incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int. 2006;97(6):1234–1241. doi:10.1111/j.1464-410X.2006.06185.x16686718
   PubMed Web of Science ®Google Scholar
• Cannon T, Chancellor M. Pharmacotherapy for stress urinary incontinence. Rev Urol. 2003;5:135–141.16985634
   PubMedGoogle Scholar
• Sacco E, Tienforti D, D’Addessi A, et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol. 2010;2:11–243. doi:10.2147/OAJU.S416624198609
   PubMedGoogle Scholar
• Sacco E. Physiopathology of overactive bladder syndrome. Urologia. 2012;79(1):24–35. doi:10.5301/RU.2012.8972
   PubMedGoogle Scholar
• Bientinesi R, Sacco E. Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. Expert Opin Pharmacother. 2018;19(18):1989–1997. doi:10.1080/14656566.2018.153250230304645
   PubMed Web of Science ®Google Scholar
• Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol. 1999;161(6):1809–1812. doi:10.1016/S0022-5347(05)68810-610332441
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279–290.9647869
   PubMed Web of Science ®Google Scholar
• Goepel M, Gronewald A, Krege S, Michel MC. Muscarinic receptor subtypes in porcine detrusor: comparison with humans and regulation by bladder augmentation. Urol Res. 1998;26(2):149–154. doi:10.1007/s0024000500389631949
   PubMedGoogle Scholar
• Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006a;148(5):565–578. doi:10.1038/sj.bjp.070678016751797
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T. The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia. J Pharmacol Sci. 2015;128(2):65–70. doi:10.1016/j.jphs.2015.05.00526084660
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol. 2004;3(1):46–53. doi:10.1016/S1474-4422(03)00622-714693111
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–562. doi:10.1016/j.eururo.2008.06.04718599186
   PubMed Web of Science ®Google Scholar
• Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62(6):1040–1060. doi:10.1016/j.eururo.2012.08.06022999811
   PubMed Web of Science ®Google Scholar
• Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline amendment 2019. J Urol. 2019;202(3):558–563. doi:10.1097/JU.000000000000030931039103
   PubMed Web of Science ®Google Scholar
• Herbison P, McKenzie JE. Which anticholinergic is best for people with overactive bladders? A network meta-analysis. Neurourol Urodyn. 2018;38(2):1–10.
   Web of Science ®Google Scholar
• Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur Urol. 2007;51(4):907–914. doi:10.1016/j.eururo.2006.11.03317157979
   PubMed Web of Science ®Google Scholar
• Ouslander JG, Wood AJJ. Management of overactive bladder. N Engl J Med. 2004;350(8):786–799. doi:10.1056/NEJMra03266214973214
   PubMed Web of Science ®Google Scholar
• Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monitor. 2000;6:314–318.
   PubMedGoogle Scholar
• Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case–control study. BMJ. 2018;361:k1315. doi:10.1136/bmj.k131529695481
   PubMed Web of Science ®Google Scholar
• Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73(6):721–732. doi:10.1001/jamaneurol.2016.058027088965
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Thai S, Iglay K, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40(1):28–37. doi:10.1002/nau.2453633098213
   PubMed Web of Science ®Google Scholar
• Wagg A, Arumi D, Herschorn S, et al. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing. 2017;46:620–626.28057620
   PubMed Web of Science ®Google Scholar
• Wagg A, Dale M, Tretter R, Stow B, Compion G. Randomized, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64(1):74–81. doi:10.1016/j.eururo.2013.01.00223332882
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–1300. doi:10.1111/j.1742-1241.2010.02433.x20561092
   PubMed Web of Science ®Google Scholar
• Yonguc T, Sefik E, Inci I, et al. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease. World J Urol. 2020;38(8):2013–2019. doi:10.1007/s00345-019-02981-731642953
   PubMed Web of Science ®Google Scholar
• Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double‐blind, placebo‐controlled Phase II dose‐finding study of the novel anti‐muscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2008;15(9):809‐815. doi:10.1111/j.1442-2042.2008.02104.x
   Web of Science ®Google Scholar
• Pushkar DY, Kasyan GR, Kolontarev KB, Sharvadze GG, Mukhametshina EI. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder. Neurourol Urodyn. 2019;38(5):1313–1321. doi:10.1002/nau.2398030888691
   PubMed Web of Science ®Google Scholar
• Wu JP, Peng L, Zeng X, et al. Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome? Int Urogynecol J. 2020;32(5). doi:10.1007/s00192-020-04329-x
   Web of Science ®Google Scholar
• Salcedo C, Davalillo S, Cabellos J, et al. In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009;156(5):807–817. doi:10.1111/j.1476-5381.2008.00082.x19222482
   PubMed Web of Science ®Google Scholar
• Song M, Kim JH, Lee KS, et al. The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomized, double-blind, placebo-controlled phase 2 study. Int J Clin Pract. 2015;69(2):242–250. doi:10.1111/ijcp.1254025363415
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9(4):433–448. doi:10.1517/17460441.2014.89292324559030
   PubMed Web of Science ®Google Scholar
• Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30. doi:10.1002/nau.2250524127366
   PubMed Web of Science ®Google Scholar
• Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol. 2012;4(6):315–324. PMID: 23205058; PMCID: PMC3491758. doi:10.1177/175628721245711423205058
   PubMedGoogle Scholar
• Ko KJ, Choo MS, Chang YS, Kim JC, Lee KS. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study). Neurourol Urodyn. 2020;39(8):2417–2424. doi:10.1002/nau.2450532894793
   PubMed Web of Science ®Google Scholar
• Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of β3-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–323. doi:10.1016/j.eururo.2015.09.00726422675
   PubMed Web of Science ®Google Scholar
• White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;12(11):768–778.e1. doi:10.1016/j.jash.2018.08.00130181042
   PubMed Web of Science ®Google Scholar
• Kelleher C, Hakimi Z, Zur R, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–333. doi:10.1016/j.eururo.2018.03.02029699858
   PubMed Web of Science ®Google Scholar
• Soda T, Tashiro Y, Koike S, Ikeuchi R, Okada T. Overactive bladder medication: persistence, drug switching, and reinitiation. Neurourol Urodyn. 2020;39(8):2527–2534. doi:10.1002/nau.2452732985716
   PubMed Web of Science ®Google Scholar
• Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Safety and tolerability results from the PILLAR study: a Phase IV, double-blind, randomized, placebo-controlled study of mirabegron in patients ≥ 65 years with overactive bladder-wet. Drugs Aging. 2020;37(9):665–676. doi:10.1007/s40266-020-00783-w32725584
   PubMed Web of Science ®Google Scholar
• Griebling TL, Campbell NL, Mangel J, et al. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: moCA results from a Phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020;20(1):109. doi:10.1186/s12877-020-1474-732183741
   PubMed Web of Science ®Google Scholar
• Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609–623. doi:10.1021/acs.jmedchem.5b0137226709102
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T. Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled Phase 3 study. Eur Urol. 2018;73(5):783–790. doi:10.1016/j.eururo.2017.12.02229366513
   PubMed Web of Science ®Google Scholar
• Yoshida M, Takeda M, Gotoh M, et al. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. BJU Int. 2020;125(5):709–717. doi:10.1111/bju.1502031991511
   PubMed Web of Science ®Google Scholar
• Mitcheson HD, Samanta S, Muldowney K, et al. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an Overactive bladder: a multicenter, Phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019;75(2):274–282. doi:10.1016/j.eururo.2018.10.00630661513
   PubMed Web of Science ®Google Scholar
• Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. International Phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316–324. doi:10.1097/JU.000000000000080732068484
   PubMed Web of Science ®Google Scholar
• Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204–216. doi:10.1177/204209861665941227695622
   PubMed Web of Science ®Google Scholar
• Kennelly MJ, Rhodes T, Girman CJ, Thomas E, Shortino D, Mudd PN Jr. Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison [published online ahead of print, 2021 Sep 18]. Adv Ther. 2021. doi:10.1007/s12325-021-01902-8
   Web of Science ®Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012;62(5):834–840. doi:10.1016/j.eururo.2012.05.05322695239
   PubMed Web of Science ®Google Scholar
• Maruyama I, Yonekubo S, Tatemichi S, et al. Effects of ritobegron (KUC-7483), a novel β3-adrenoceptor agonist, on both rat bladder function following partial bladder outlet obstruction and on rat salivary secretion: a comparison with the effects of tolterodine. J Smooth Muscle Res. 2012;48(5–6):115–124. doi:10.1540/jsmr.48.11523538508
   PubMedGoogle Scholar
• Tzoumas N, Farrah TE, Dhaun N, Webb DJ. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. Br J Pharmacol. 2020;177(24):5467–5488. doi:10.1111/bph.1492031721165
   PubMed Web of Science ®Google Scholar
• Lee WC, Chiang PH, Tain YL, et al. Sensory dysfunction of bladder mucosa and bladder oversensitivity in a rat model of metabolic syndrome. PLoS One. 2012;7(9):e45578. doi:10.1371/journal.pone.004557823029112
   PubMed Web of Science ®Google Scholar
• Lee WC, Leu S, Wu KLH, Tain YL, Chuang YC, Chan JYH. Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats. Sci Rep. 2021;11(1):8202. doi:10.1038/s41598-021-87505-333859259
   PubMed Web of Science ®Google Scholar
• Dell’Atti L. Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients. Eur Rev Med Pharmacol Sci. 2015;19(9):1559–1563.26004592
   PubMed Web of Science ®Google Scholar
• Chen H, Wang F, Yu Z, et al. Efficacy of daily low-dose tadalafil for treating overactive bladder: results of a randomized, double-blind, placebo-controlled trial. Urology. 2017;100:59–64. doi:10.1016/j.urology.2016.11.00827845219
   PubMed Web of Science ®Google Scholar
• Giuliano FA, Lamb J, Crossland A, Haughie S, Ellis P, Tamimi NA. A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder. BJU Int. 2010;106(5):666–673. doi:10.1111/j.1464-410X.2010.09205.x20151971
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of mirabegron add‐on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4‐Week solifenacin monotherapy: a randomized double‐blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–145. doi:10.1016/j.eururo.2016.02.03026965560
   PubMed Web of Science ®Google Scholar
• Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–575. doi:10.1111/bju.1388228418102
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, doubleblind, dose‐ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–588. doi:10.1016/j.eururo.2014.02.01224612659
   PubMed Web of Science ®Google Scholar
• Gibson W, MacDiarmid S, Huang M, et al. Treating overactive bladder in older patients with a combination of Mirabegron and Solifenacin: a prespecified analysis from the BESIDE study. Eur Urol Focus. 2017;3(6):629–638. doi:10.1016/j.euf.2017.08.00828916436
   PubMedGoogle Scholar
• Yamanishi T, Kaga K, Sakata K, et al. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn. 2020;39(2):804–812. doi:10.1002/nau.2428531961963
   PubMed Web of Science ®Google Scholar
• Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder. Low Urin Tract Symptoms. 2017;9(1):27–32. doi:10.1111/luts.1210328120445
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance. Ther Adv Urol. 2014;6(6):215–223. doi:10.1177/175628721454489625435915
   PubMedGoogle Scholar
• Chancellor MB, Yehoshua A, Waweru C, et al. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. Int Urol Nephrol. 2016;48(7):1029–1036. doi:10.1007/s11255-016-1277-027032397
   PubMed Web of Science ®Google Scholar
• Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):583–598. doi:10.1007/s00192-007-0529-z18196198
   PubMed Web of Science ®Google Scholar
• Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249. doi:10.1016/j.eururo.2013.04.00123608668
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a Phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186. doi:10.1016/j.juro.2012.12.02223246476
   PubMed Web of Science ®Google Scholar
• Herschorn S, Kohan A, Aliotta P, et al. The efficacy and safety of onabotulinumtoxinA or Solifenacin compared with placebo in Solifenacin naïve patients with refractory overactive bladder: results from a multicenter, randomized, double-blind Phase 3b trial. J Urol. 2017;198(1):167–175. doi:10.1016/j.juro.2017.01.06928161352
   PubMed Web of Science ®Google Scholar
• Ferreira RS, D’Ancona CAL, Oelke M, Carneiro MR. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial. Einstein. 2018;16(3):eAO4207. doi:10.1590/S1679-45082018AO420730088545
   PubMed Web of Science ®Google Scholar
• Nitti VW, Ginsberg D, Sievert KD, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791–800. doi:10.1016/j.juro.2016.03.14627038769
   PubMed Web of Science ®Google Scholar
• Lozano-Ortega G, Walker D, Rogula B, et al. The relative efficacy and safety of Mirabegron and OnabotulinumtoxinA in patients with overactive bladder who have previously been managed with an Antimuscarinic: a network meta-analysis. Urology. 2019;127:1–8. doi:10.1016/j.urology.2019.02.00530790650
   PubMed Web of Science ®Google Scholar
• Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784–795. doi:10.1016/j.eururo.2011.07.00121782318
   PubMed Web of Science ®Google Scholar
• Peyronnet B, Castel-Lacanal E, Roumiguie M, et al. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: a case control study. Neurourol Urodyn. 2017;36(3):734–739. doi:10.1002/nau.2300927037973
   PubMed Web of Science ®Google Scholar
• Bottet F, Peyronnet B, Boissier R, et al. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Neurourol Urodyn. 2018;37(1):291–297. doi:10.1002/nau.2329128431196
   PubMed Web of Science ®Google Scholar
• Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61(6):1178. doi:10.1016/j.eururo.2012.01.04622306320
   PubMed Web of Science ®Google Scholar
• Mushrush DJ, Koteiche HA, Sammons MA, Link AJ, McHaourab HS, Lacy DB. Studies of the mechanistic details of the pH-dependent association of botulinum neurotoxin with membranes. J Biol Chem. 2011;286(30):27011–27018. doi:10.1074/jbc.M111.25698221652698
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009;182(2):786–792. doi:10.1016/j.juro.2009.03.08319539320
   PubMed Web of Science ®Google Scholar
• Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. Bladder instillation of liposome encapsulated onabotulinumtoxinA improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol. 2014;192(6):1743–1749. doi:10.1016/j.juro.2014.07.00825046622
   PubMed Web of Science ®Google Scholar
• Tyagi P, Li Z, Chancellor M, De Groat WC, Yoshimura N, Huang L. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res. 2004;21(5):832. doi:10.1023/B:PHAM.0000026436.62869.9c15180342
   PubMed Web of Science ®Google Scholar
• Rappaport YH, Zisman A, Jeshurun-Gutshtat M, et al. Safety and feasibility of intravesical instillation of Botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: a pilot study. Urology. 2018;114:60–65. doi:10.1016/j.urology.2017.12.02829307733
   PubMed Web of Science ®Google Scholar
• Chen D, Song D, Wientjes MG, Au JL. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res. 2003;9(1):363–369.12538489
   PubMed Web of Science ®Google Scholar
• Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc. 2009;84(8):702–706. doi:10.1016/S0025-6196(11)60520-X19648387
   PubMed Web of Science ®Google Scholar
• Cetinel S, Ercan F, Sirvanci S, et al. The ameliorating effect of melatonin on protamine sulfate induced bladder injury and its relationship to interstitial cystitis. J Urol. 2003;169(4):1564–1568. doi:10.1097/01.ju.0000049649.80549.1712629416
   PubMed Web of Science ®Google Scholar
• Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology. 2005;66(1):208–212. doi:10.1016/j.urology.2005.01.05515992889
   PubMed Web of Science ®Google Scholar
• Asai T, Tsuzuku T, Takahashi S, et al. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery. Biochem Biophys Res Commun. 2014;444(4):599–604. doi:10.1016/j.bbrc.2014.01.10724486551
   PubMed Web of Science ®Google Scholar
• Nagai J, Komeda T, Katagiri Y, Yumoto R, Takano M. Characterization of protamine uptake by opossum kidney epithelial cells. Biol Pharm Bull. 2013;36(12):1942–1949. doi:10.1248/bpb.b13-0055324292053
   PubMed Web of Science ®Google Scholar
• Tyagi P, Banerjee R, Basu S, Yoshimura N, Chancellor M, Huang L. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol Pharm. 2006;3(4):398. doi:10.1021/mp050093x16889433
   PubMed Web of Science ®Google Scholar
• Glogau R, Blitzer A, Brandt F, Kane M, Monheit GD, Waugh JM. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 2012;11(1):38–45.22206075
   PubMed Web of Science ®Google Scholar
• Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, Sharifi-Rad L, Nejat F, Bazargan-Hejazi S. Intravesical electromotive botulinum toxin type A administration–part II: clinical application. Urology. 2011;77(2):439–445. doi:10.1016/j.urology.2010.06.00320800886
   PubMed Web of Science ®Google Scholar
• Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, Sabetkish S, Ladi-Seyedian S, Sotoudeh M. Intravesical electromotive administration of botulinum toxin type A in improving the bladder and bowel functions: evidence for novel mechanism of action. J Spinal Cord Med. 2021;44(1):89–95. doi:10.1080/10790268.2019.160349030998432
   PubMed Web of Science ®Google Scholar
• Kodama T, Tomita Y, Koshiyama K, Blomley MJ. Transfection effect of microbubbles on cells in superposed ultrasound waves and behavior of cavitation bubble. Ultrasound Med Biol. 2006;32(6):905–914. doi:10.1016/j.ultrasmedbio.2006.03.00416785012
   PubMed Web of Science ®Google Scholar
• Chuang YC, Huang TL, Tyagi P, Huang CC. Urodynamic and immunohistochemical evaluation of intravesical botulinum Toxin A delivery using low energy shock waves. J Urol. 2016;196(2):599–608. doi:10.1016/j.juro.2015.12.07826724396
   PubMed Web of Science ®Google Scholar
• Nambiar AK, Bosch R, Cruz F, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018;73(4):596–609. doi:10.1016/j.eururo.2017.12.03129398262
   PubMed Web of Science ®Google Scholar
• Wróbel A, Serefko A, Woźniak A, et al. Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways. Pharmacol Biochem Behav. 2020;189:172842. doi:10.1016/j.pbb.2019.17284231899220
   PubMed Web of Science ®Google Scholar
• Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol. 2007;51:67–74.17014950
   PubMed Web of Science ®Google Scholar
• Bump RC, Voss S, Beardsworth A, Manning M, Zhao YD, Chen W. Long-term efficacy of duloxetine in women with stress urinary incontinence. BJU Int. 2008;102(2):214–218. doi:10.1111/j.1464-410X.2008.07577.x18422764
   PubMed Web of Science ®Google Scholar
• Mirzaei M, Daneshpajooh A, Anvari SO, Dozchizadeh S, Teimorian M. Evaluation of the clinical efficacy and complications of Duloxetine in comparison to solifenacin in the treatment of overactive bladder disease in women: a randomized clinical trial [published online ahead of print, 2021 Aug 3]. Urol J. 2021. doi:10.22037/uj.v18i.6274
   Web of Science ®Google Scholar
• Lee MJ, Moon JH, Lee HK, Cho CH, Choi SH, Im WB. Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. Eur J Pharmacol. 2019;843:240–250. doi:10.1016/j.ejphar.2018.11.03730502343
   PubMed Web of Science ®Google Scholar
• Choi JB, Jeon SH, Kwon EB, et al. The effects of oral administration of the novel muscarinic receptor antagonist DA-8010 on overactive bladder in rat with bladder outlet obstruction. BMC Urol. 2020;20(1):41. doi:10.1186/s12894-020-00611-832303205
   PubMed Web of Science ®Google Scholar
• Son H, Kim J, Kim H, et al. MP02-18 efficacy and safety of DA8010, a novel M3 antagonist, in patients with overactive bladder: randomized, double-blind, Phase 2 study. J Urol. 2021;206(Supplement 3):e19. doi:10.1097/ju.0000000000001963.18
   Google Scholar
• Rovner E, Chai TC, Jacobs S, et al. Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020;39(2):744–753. doi:10.1002/nau.2427231945197
   PubMed Web of Science ®Google Scholar
• Wróbel A, Serefko A, Poleszak E, Rechberger T. Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms. Int Urogynecol J. 2016;27(11):1713–1721. doi:10.1007/s00192-016-3027-327142032
   PubMed Web of Science ®Google Scholar
• Wróbel A, Doboszewska U, Rechberger E, Wlaź P, Rechberger T. SN003, a CRF1 receptor antagonist, attenuates depressive-like behavior and detrusor overactivity symptoms induced by 13-cis-retinoic acid in rats. Eur J Pharmacol. 2017;812:216–224. doi:10.1016/j.ejphar.2017.07.01028705713
   PubMed Web of Science ®Google Scholar
• Mukerji G, Yiangou Y, Corcoran SL, et al. Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urol. 2006;6(1):6. doi:10.1186/1471-2490-6-616519806
   PubMedGoogle Scholar
• Aizawa N, Fujimori Y, Nakanishi O, et al. Efficacy of the combination of KPR-5714, a novel transient receptor potential melastatin 8 (TRPM8) antagonist, and β3-adrenoceptor agonist or anticholinergic agent on bladder dysfunction in rats with bladder overactivity. Eur J Pharmacol. 2021;899:173995. doi:10.1016/j.ejphar.2021.17399533675781
   PubMed Web of Science ®Google Scholar
• Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomized placebo-controlled trial (CAMS-LUTS). Int Urogynecol J. 2006;17(6):636–641. doi:10.1007/s00192-006-0086-x
   PubMed Web of Science ®Google Scholar
• Kavia R, De Ridder D, Constantinescu C, Stott C, Fowler CJ, Constantinescu CS. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler J. 2010;16(11):1349–1359. doi:10.1177/1352458510378020
   PubMed Web of Science ®Google Scholar
• Wróbel A, Szopa A, Serefko A, Poleszak E. A novel alternative in the treatment of detrusor overactivity? In vivo activity of O-1602, the newly synthesized agonist of GPR55 and GPR18 Cannabinoid receptors. Molecules. 2020;25(6):1384. doi:10.3390/molecules25061384
   Web of Science ®Google Scholar
• Bientinesi R, Mancuso C, Martire M, et al. KV7 channels in the human detrusor: channel modulator effects and gene and protein expression. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(2):127–137. doi:10.1007/s00210-016-1312-927761601
   PubMed Web of Science ®Google Scholar
• Aizawa N, Wakamatsu D, Kida J, et al. Inhibitory effects of retigabine, a Kv7 channel activator, on mechanosensitive primary bladder afferent activities and nociceptive behaviors in rats. Neurourol Urodyn. 2017;36(2):280–285. doi:10.1002/nau.2292026536146
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (U.S.). A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of-concept study to assess the efficacy and safety of BAY 1817080 in patients With Overactive Bladder (OAB) over a 12-week treatment period. Identifier NCT04545580; (2020, September – 2022, February). Available from: https://clinicaltrials.gov/ct2/show/NCT04545580. Accessed November 7, 2021.
   Google Scholar
• Li M, Wang Y, Banerjee R, et al. Molecular mechanisms of human P2X3 receptor channel activation and modulation by divalent cation bound ATP. Elife. 2019;8:e47060. doi:10.7554/eLife.47060
   Google Scholar
• Ford AP, Undem BJ. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013;7:267. doi:10.3389/fncel.2013.00267
   Google Scholar
• Peyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000. doi:10.1016/j.eururo.2019.02.038
   Google Scholar
• Malde S, Apostilidis A, Selai C, et al. Botulinum toxin A for refractory OAB and idiopathic urinary retention: can phenotyping improve outcome for patients: ICI-RS 2019? Neurourol Urodyn. 2020;39(Suppl 3):S104–S112. doi:10.1002/nau.2420731692092
   PubMed Web of Science ®Google Scholar